ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01441193
Recruitment Status : Terminated (Enrollments were suspended due to delta-V2 Env unavailability, following the EMA/CHMP/BWP/534898/2008 guideline, not allowing the use of a retest date)
First Posted : September 27, 2011
Last Update Posted : March 4, 2016
Sponsor:
Collaborator:
Novartis Vaccines
Information provided by (Responsible Party):
Barbara Ensoli, MD, Istituto Superiore di Sanità

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : February 2014
  Actual Study Completion Date : February 2014
Publications: